Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 13/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427683 | 0.84 | RORC (0.46) | ADRA2CESR2RORC | |
| SCHEMBL3555287 | 0.80 | CHKA (0.46) | RORC | |
| SCHEMBL3552127 | 0.79 | MCHR1 (0.47) | RORC | |
| SCHEMBL3554859 | 0.76 | MAPK1 (0.44) | RORC | |
| SCHEMBL24352439 | 0.76 | ADRA2A (0.43) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL29310072 | 0.76 | ADRA2A (0.43) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL25839419 | 0.76 | ADRA2A (0.43) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL2199776 | 0.74 | CHRNB4 (0.39) | — | |
| SCHEMBL1921934 | 0.74 | USP2 (0.58) | ADRA2AADRA2CADRA2BESR1ESR2 | |
| SCHEMBL3549591 | 0.73 | ACACB (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | ADRA2A 4530/4885ADRA2C 4300/4885ADRA2B 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.